CD226 and neoplasm: There was a significant difference in the proportions of NKp30, NKp46, NKG2D, and DNAM-1 expressing peripheral blood NK cells between stage I-II and stage III-IV GC patients, and NK cell receptor expression levels were negatively associated with tumor stage (Figure 5).